Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11623286 | 0.91 | SMN1; SMN2 (0.82) | SMN1; SMN2KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL29040265 | 0.91 | SMN1; SMN2 (0.82) | SMN1; SMN2KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL6667166 | 0.88 | SMN1; SMN2 (0.79) | SMN1; SMN2KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL7756182 | 0.88 | SMN1; SMN2 (0.79) | SMN1; SMN2KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL6783522 | 0.86 | SMN1; SMN2 (0.75) | SMN1; SMN2KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL11623002 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL3749067 | 0.84 | SMN1; SMN2 (0.72) | SMN1; SMN2KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL1298734 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL1298732 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL13969980 | 0.82 | KMT2A (0.69) | SMN1; SMN2KDM4EMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2785688-B1 | A PROCESS FOR THE MANUFACTURE OF CHIRAL CATALYSTS AND THEIR SALTS | SCINOPHARM TAIWAN LTD (TW) | 2017-09-13 | — | — | EP | disclosed |
| US-8865893-B2 | Method for preparing 2-morpholinoisobornane-10-thiol and intermediates formed therein | NATIONAL TSING HUA UNIVERSITY (TW) | 2014-10-21 | — | — | US | disclosed |
| US-8865893-B2 | Method for preparing 2-morpholinoisobornane-10-thiol and intermediates formed therein | NATIONAL TSING HUA UNIVERSITY (TW) | 2014-10-21 | — | — | US | disclosed |
| US-8859765-B2 | Process for the manufacture of chiral catalysts and their salts | SCINOPHARM TAIWAN, LTD. (TW) | 2014-10-14 | — | — | US | disclosed |
| CN-102234255-B | Process for the preparation of 2-morpholinoisobutane-10-thiols and intermediates formed thereby | NAT UNIV TSING HUA | 2013-05-08 | — | — | CN | disclosed |
| CN-102234255-A | Process for the preparation of 2-morpholinoisobutane-10-thiols and intermediates formed thereby | NAT UNIV TSING HUA | 2011-11-09 | — | — | CN | disclosed |
| US-20110269955-A1 | METHOD FOR PREPARING 2-MORPHOLINOISOBORNANE- 10-THIOL AND INTERMEDIATES FORMED THEREIN | NATIONAL TSING HUA UNIVERSITY (TW) | 2011-11-03 | — | — | US | disclosed |
| US-20110269955-A1 | METHOD FOR PREPARING 2-MORPHOLINOISOBORNANE- 10-THIOL AND INTERMEDIATES FORMED THEREIN | NATIONAL TSING HUA UNIVERSITY (TW) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269955-A1 | METHOD FOR PREPARING 2-MORPHOLINOISOBORNANE- 10-THIOL AND INTERMEDIATES FORMED THEREIN | MPST, TST, TMT1A | SMN1; SMN2 72/4885KDM4E 4287/4885MEN1 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.